TLP Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

TLP Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,980	Closed	-$238K	–	568
2017 Q2	$238K	Sell	2,980 -4,441	-60%	-$284K	0.22%	161
2017 Q1	$380K	Buy	+7,421	New	+$343K	0.26%	91

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TLP Group's ALNY Position: Q3 2017 in Review

TLP Group sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2017, closing a stake of 2,980 shares — an estimated $238K sold.

TLP Group first reported a position in ALNY in Q1 2017 and held it in 2 quarters. The position peaked at $380K in Q1 2017. 236 funds tracked by Wall St. Rank hold ALNY as of Q3 2017.

TLP Group reported no remaining Alnylam Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
TLP Group sold 2,980 Alnylam Pharmaceuticals shares in Q3 2017, an estimated $238K.
TLP Group first reported a position in Alnylam Pharmaceuticals in Q1 2017 and held it in 2 quarters.
TLP Group's Alnylam Pharmaceuticals position peaked at $380K in Q1 2017.
236 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2017.

Based on TLP Group's 13F filing for Q3 2017, filed 14 Nov 2017.